Kevin holds a bachelor of science degree in bioengineering from Purdue University and a master of business administration degree from Indiana University’s Kelley School of Business.
Executive Vice President
Faruk Abdullah, Vice President at Promidian, is a life sciences professional with extensive experience addressing a broad range of strategic issues including corporate development, portfolio planning, and launch excellence.
Prior to joining Promidian, Faruk was a Vice President at Applied Predictive Technologies (APT). Faruk led the Life Sciences and Healthcare practice at APT, where he helped clients apply advanced analytic software technologies to draw unique insights from clinical and commercial data. Before joining APT, Faruk was an Associate Partner at the Monitor Group, where he focused on shaping and executing strategic initiatives for large and mid-cap life science companies. In addition to being a strategic advisor, Faruk has contributed to entrepreneurial efforts developing products in both the therapeutic and medical device spaces.
Faruk has authored a number of articles that have helped companies consider novel approaches to developing and commercializing their products. He has shared unique perspectives on how companies can adapt their commercial models to an evolving healthcare ecosystem. He also has offered insights on how organizations can rethink how to develop and integrate analytic capabilities to inform critical strategic decisions.
Faruk holds a bachelor of science degree in electrical engineering from Northwestern University and an MBA from Harvard Business School.
Kari Edwards, PhD, Vice President at Promidian, has 16 years of global life sciences experience and a diverse professional background spanning academic, management consulting, and industry settings.
Kari advises life science clients on innovative ways by which to define, substantiate, and communicate product value; optimize pricing and market access strategies; and develop compelling, patient-centered commercial and medical plans to meet the needs of a progressively complex stakeholder mix. Increasingly, Kari works with clients to harness insights from real-world data to improve treatment decision-making, enhance product value, and facilitate contracting and reimbursement.
Prior to joining Promidian, Kari occupied a number of executive and leadership roles, most recently as Divisional Principal within ICON’s Commercialization and Outcomes consulting division and as Vice President, Research and Business Strategy at Precision Health Economics (now Precision for Value). Kari’s acute appreciation of client needs and the strategic, tactical, and operational complexities facing manufacturers is grounded in and bolstered by her nine years at Amgen, where she worked at the interstices of global medical and commercial functions in a variety of roles.
Kari began her career on the faculty of Brown University, where her novel research program and methodological innovations earned her national recognition and grant support from the National Science Foundation. The recipient of a number of research and teaching awards, Dr. Edwards has authored papers in top-tier, peer-reviewed professional journals and presented at industry and professional conferences in the US and Europe.
Kari received a bachelor of arts degree in psychology from UC Berkeley, a master’s degree from Yale University in cognitive psychology, and a PhD in cognitive-social psychology from the University of Michigan.
A Vice President with Promidian, Jonathan has more than 15 years of experience helping biopharmaceutical companies make better strategic decisions in the areas of commercialization, R&D, portfolio planning, launch pricing and reimbursement, forecasting, asset valuation, and more across a broad range of therapeutic areas.
Jonathan’s experience spans both commercial and market access questions, and the development and application of both quantitative and qualitative insights. As such, he brings particularly deep expertise in leveraging innovative methodologies and large data sets to support analysis and strategic decision-making.
Before joining Promidian, Jonathan served as Principal at Putnam Associates, where he contributed to the growth of the firm’s New Products Strategy and Pricing, Reimbursement and Market Access practices. As Senior Principal at the Amundsen Group, Jonathan blended insights from large quantitative data sets with qualitative and secondary research to drive actionable recommendations for clients. He also previously served as a strategy consultant at L.E.K. Consulting, where he was largely focused on forecasting and valuation, as well as asset screens and business development strategy for smaller biotech companies. Jonathan has also served in several roles at Vertex Pharmaceuticals.
Jonathan has lectured on valuation approaches and techniques at the Massachusetts Biotechnology Council, and he is co-author of “Biopharma: Beyond the First Product,” an in-depth look at critical success factors for growth of emerging biotechs, published in In Vivo.
Jonathan earned a bachelor of arts in economics from Dartmouth College and an MBA from Harvard Business School.